Compare First Citizens BancShares Inc (FCNCA) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Citizens BancShares Inc vs Novavax Inc — how do they compare? First Citizens BancShares Inc trades at $2,249.28 (market cap $24.84B), while Novavax Inc trades at $7.97 (market cap $1.30B). The key difference: First Citizens BancShares Inc is far larger — about 19.1× Novavax Inc's market cap, and First Citizens BancShares Inc pays a 0.38% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| FCNCA | NVAX | |
|---|---|---|
Market Cap | $24.84B | $1.30B |
Sector | Sector/Thematic | Health |
52-Week High | $2.25K | $11.19 |
52-Week Low | $1.64K | $6.22 |
Dividend Yield | 0.38% | — |
Enterprise Value | — | $879.40M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Citizens BancShares (FCNCA) trades at $2,218.49, down 0.85% on the day, with strong technical indicators showing a bullish trend. The company demonstrates solid fundamentals with a P/E of 11.98, net income margin of 25.23%, and consistent earnings beats in recent quarters. Recent business developments include expansion of working capital finance services and strategic leadership appointments to drive growth across central U.S. markets.
FCNCA presents a mixed outlook with strong profitability metrics and positive earnings momentum offset by cautious analyst sentiment (81.82% hold rating). The stock trades below consensus price target of $2,310, offering potential upside, though risks include contracting net interest margins and elevated uninsured deposits at 38.3% of total deposits.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
